PDS Biotechnology Corporation
PDS Biotechnology Corporation (PDSB) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · PDSB · as of Sep 30, 2025
Ownership Breakdown
49
Institutional Holders
▼ 8 vs Q2
$6.64M
Total Inst. Value
▼ $3.26M vs Q2
55.82M
Shares Outstanding
freeFloat 97.47%
5.62M
13F Shares Held
▼ 1.83M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
PDSB largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
VANGUARD GROUP INC pharmaceutical preparations | 1.90M | 4.14% | 4.14% | $1.92B | Nov 7, 2025 | ▼ 49.9K |
BLACKROCK, INC. pharmaceutical preparations | 517.5K | 1.13% | 1.13% | $522.69M | Nov 12, 2025 | ▲ 3.1K |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 482.0K | 1.05% | 1.05% | $486.91M | Nov 12, 2025 | ▲ 64.1K |
CITADEL ADVISORS LLC pharmaceutical preparations | 386.4K | 84.18% | 84.18% | $390.29M | Nov 14, 2025 | ▲ 137.4K |
INSPIRION WEALTH ADVISORS, LLC pharmaceutical preparations | 344.4K | 75.03% | 75.03% | $1.32B | Oct 6, 2025 | ▲ 265.9K |
SQUAREPOINT OPS LLC pharmaceutical preparations | 291.6K | 63.53% | 63.53% | $294.54M | Nov 14, 2025 | ▲ 193.9K |
RENAISSANCE TECHNOLOGIES LLC pharmaceutical preparations | 275.9K | 60.10% | 60.10% | $278.62M | Nov 13, 2025 | ▲ 170.2K |
BLAIR WILLIAM & CO/IL pharmaceutical preparations | 250.0K | 54.46% | 54.46% | $252.50M | Nov 12, 2025 | — held |
CAPTION MANAGEMENT, LLC pharmaceutical preparations | 219.0K | 47.71% | 47.71% | $221.19M | Nov 14, 2025 | ▲ 219.0K |
UBS GROUP AG pharmaceutical preparations | 200.2K | 43.62% | 43.62% | $202.24M | Nov 13, 2025 | ▼ 342.8K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
12
Increased
+1.22M shares6
New Positions
first time holders15
Decreased
−481.8K shares1
Sold Out
fully exitedNet shares change (top 50)
+741.3K
+1.22M / −481.8K
Net new holders
+2
6 new / 1 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
PDSB insider trading · insider activity
Source: SEC Form 4
5
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
BEDU-ADDO FRANK President/CEO | Jan 12, 2026 | Award | 548,782 | $0.98 | $537.8K | 548.8K | Form 4 ↗ |
CONN GREGORY Chief Scientific Officer | Jan 12, 2026 | Award | 150,000 | $0.98 | $147.0K | 150.0K | Form 4 ↗ |
Shepard Kirk V. Chief Medical Officer | Jan 12, 2026 | Award | 300,000 | $0.98 | $294.0K | 300.0K | Form 4 ↗ |
Boesgaard Lars Chief Financial Officer | Jan 12, 2026 | Award | 300,000 | $0.98 | $294.0K | 300.0K | Form 4 ↗ |
Brown Spencer D. Senior VP, General Counsel | Jan 12, 2026 | Award | 300,000 | $0.98 | $294.0K | 300.0K | Form 4 ↗ |
Toutain Stephan Chief Operating Officer | Jan 12, 2026 | Award | 300,000 | $0.98 | $294.0K | 300.0K | Form 4 ↗ |
Freitag Gregory Gene director | Jan 12, 2026 | Award | 54,876 | $0.98 | $53.8K | 54.9K | Form 4 ↗ |
Iliev Ilian director | Jan 12, 2026 | Award | 54,876 | $0.98 | $53.8K | 54.9K | Form 4 ↗ |
Ali-Jackson Kamil director | Jan 12, 2026 | Award | 54,876 | $0.98 | $53.8K | 54.9K | Form 4 ↗ |
BRAWLEY OTIS W director | Jan 12, 2026 | Award | 54,876 | $0.98 | $53.8K | 54.9K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
PDS Biotechnology Corporation (PDSB) is primarily owned by institutional investors, who hold approximately 10.1% of total shares outstanding. Company insiders own approximately 2.53%, while retail and public investors account for the remaining 87.40%.
The largest institutional shareholder of PDS Biotechnology Corporation is VANGUARD GROUP INC, holding approximately 1.90 million shares — equal to 4.14% of outstanding shares — as of September 30, 2025.
A total of 49 institutional investors currently hold PDSB stock, with a combined institutional value of approximately $6,638,921 as of the most recent 13F filing period.
Frequently asked questions
PDSB ownershipPDS Biotechnology Corporation (PDSB) is primarily owned by institutional investors, who hold approximately 10.1% of shares. The largest shareholder is VANGUARD GROUP INC with a 4.14% stake. Company insiders hold 2.53%. Data sourced from SEC Form 13F as of September 30, 2025.